Anti-Human EGFR (Cetuximab) [Clone C225] – APC
Anti-Human EGFR (Cetuximab) [Clone C225] – APC
Product No.: LT603
Product No.LT603 Clone C225 Target EGFR Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names ErbB-1; HER1; epidermal growth factor receptor Isotype Human IgG1κ Applications FC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human EGFR/ErbB1 Product Concentration 0.2 mg/ml Formulation This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Red Laser (650 nm) RRIDAB_2893973 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Cetuximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? CyTOF® Additional Reported Applications For Relevant Conjugates ? B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Cetuximab. Clone C225 recognizes human EGFR. This product is for research use only. Background EGFR is a 170 kD transmembrane glycoprotein that is part of the ErbB family of receptors within the protein kinase superfamily. EGFR is one of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). EGFR is essential for various processes including controlling cell growth and differentiation and ductal development of the mammary glands. Ligand binding induces dimerization and autophosphorylation. It consists of a glycosylated extracellular domain which binds to EGF and an intracellular domain with tyrosine-kinase activity necessary for signal transduction. TGFα, vaccinia virus growth factor, and related growth factors can also bind to and signal through EGFR. Abnormal EGFR signaling has been implicated in inflammatory diseases such as psoriasis, eczema and atherosclerosis. Alzheimer's disease is linked with poor signaling of the EGFR and other receptor tyrosine kinases. Furthermore, over-expression of the EGFR is linked with the growth of various tumors. EGFR has been identified as an oncogene, a gene which in certain circumstances can transform a cell into a tumor cell, which has led to the therapeutic development of anticancer EGFR inhibitors. EGFR is a well-established target for both mAbs and specific tyrosine kinase inhibitors. Anti-Human EGFR (Cetuximab) utilizes the same variable regions from the therapeutic antibody Cetuximab making it ideal for research projects. Antigen Distribution EGFR is ubiquitously expressed and found in the plasma membrane. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Cetuximab biosimilars are used in pharmacokinetic (PK) bridging ELISA assays as calibration standards or reference controls to quantify drug levels in serum by generating a standard curve against which unknown sample concentrations are measured. These biosimilars serve as the analytical standard for both the biosimilar under test and the reference product, enabling direct comparison of pharmacokinetics in biosimilar development. Key aspects of their use:
ELISA Protocols:
Summary Table: Role of Biosimilar as Calibration Standard in PK Bridging ELISA
In summary: Standard flow cytometry protocols for evaluating EGFR expression levels and binding capacity with a conjugated cetuximab biosimilar (e.g., PE or APC-labeled) involve antibody-based staining of live or fixed cells, followed by detection and quantification of surface EGFR using the fluorescent signal from the conjugated antibody. Essential protocol steps and details:
Specialized assays:
Notes and controls:
This approach enables researchers to validate EGFR target expression and quantitatively assess cetuximab biosimilar binding, facilitating preclinical characterization of antibody-target interactions and potency. If a biotinylated version of cetuximab is used instead of a direct conjugate, a fluorescent streptavidin or secondary antibody is needed for detection, but the core protocol remains comparable. Biopharma companies typically use a comprehensive set of analytical assays to confirm both the structural and functional similarity of a proposed biosimilar to the originator (reference) drug. These studies use validated, often orthogonal, methods to ensure that all critical quality attributes (CQAs) of the biosimilar fall within the acceptable range defined by the reference product. Key Analytical Assays for Biosimilar Development
These assays together create a detailed head-to-head comparison of the biosimilar and the reference product, examining key molecular properties and biological functions. Results must show high similarity, even if minor differences exist—functional assays are especially critical to demonstrate that any detected differences do not affect biological performance or clinical efficacy. Role of Leinco Biosimilars in Analytical Assays
Note: The search results provided do not offer detailed accounts of the use of Leinco biosimilars in peer-reviewed publications or regulatory submissions, but their role as research and assay validation reagents is consistent with biosimilar best practices and vendor documentation. Summary Table: Key Analytical Assays for Biosimilar Comparability
This multi-tiered analytical approach is mandated by regulatory agencies to ensure biosimilars are highly similar in both structure and function to their reference products, assuring safety and efficacy for clinical use. References & Citations1. Tortora, G. et al. (1999) Clin Cancer Res. 5(4):909-16. 2. Myers, J. et al. (2006) Clin Cancer Res. 12(2): 600–607. Technical ProtocolsCertificate of Analysis |
Formats Available
